Lindsay Maggio1, David P Nicolau, Melissa DaCosta, Dwight J Rouse, Brenna L Hughes. 1. Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, and the Department of Pharmacy, Women and Infants' Hospital, Warren Alpert Medical School of Brown University, Providence, Rhode Island; and the Center for Anti-infective Research & Development, Hartford Hospital, Hartford, Connecticut.
Abstract
OBJECTIVE: To compare adipose tissue concentration among obese women receiving 2 g compared with 3 g of precesareancefazolin prophylaxis. METHODS: This was a double-blind randomized controlled trial of women with singleton gestations and body mass indexes (BMIs) of 30 or greater at their first prenatal visit undergoing cesarean delivery at term. Women were randomly allocated, stratified by BMI, to receive 2 g or 3 g of cefazolin. Subcutaneous adipose tissue was harvested twice: before (opening) fascial incision and after (closing) fascial closure. The primary outcome was opening adipose tissue cefazolin concentration, measured by high-pressure liquid chromatography. RESULTS:From April 2013 to July 2014, 58 women were enrolled, 57 included in the analysis: 28 in the 2-g group and 29 in the 3-g group. Baseline characteristics were similar between groups. Median opening adipose tissue concentration was similar between the 2-g and 3-g groups (9.4 [interquartile range 5.1-13.4] compared with 11.7 [interquartile range 7-18.3] micrograms/g, P=.12). The percentage of women with opening concentrations above 8 micrograms/g, the minimally inhibitory concentration of cefazolin for Staphylococcus species, was similar (61% compared with 72%, P=.35). All samples were above 2 micrograms/g, the minimally inhibitory concentration for Enterobacteriaceae. Closing adipose tissue concentrations and stratified analyses were consistent with the overall analysis. CONCLUSION: In obese women undergoing cesarean delivery, prophylaxis with 3 g ofcefazolin did not significantly increase adipose tissue concentration. Thus, our data do not support recommendations for 3-g dosing. LEVEL OF EVIDENCE: I.
RCT Entities:
OBJECTIVE: To compare adipose tissue concentration among obesewomen receiving 2 g compared with 3 g of precesarean cefazolin prophylaxis. METHODS: This was a double-blind randomized controlled trial of women with singleton gestations and body mass indexes (BMIs) of 30 or greater at their first prenatal visit undergoing cesarean delivery at term. Women were randomly allocated, stratified by BMI, to receive 2 g or 3 g of cefazolin. Subcutaneous adipose tissue was harvested twice: before (opening) fascial incision and after (closing) fascial closure. The primary outcome was opening adipose tissue cefazolin concentration, measured by high-pressure liquid chromatography. RESULTS: From April 2013 to July 2014, 58 women were enrolled, 57 included in the analysis: 28 in the 2-g group and 29 in the 3-g group. Baseline characteristics were similar between groups. Median opening adipose tissue concentration was similar between the 2-g and 3-g groups (9.4 [interquartile range 5.1-13.4] compared with 11.7 [interquartile range 7-18.3] micrograms/g, P=.12). The percentage of women with opening concentrations above 8 micrograms/g, the minimally inhibitory concentration of cefazolin for Staphylococcus species, was similar (61% compared with 72%, P=.35). All samples were above 2 micrograms/g, the minimally inhibitory concentration for Enterobacteriaceae. Closing adipose tissue concentrations and stratified analyses were consistent with the overall analysis. CONCLUSION: In obesewomen undergoing cesarean delivery, prophylaxis with 3 g of cefazolin did not significantly increase adipose tissue concentration. Thus, our data do not support recommendations for 3-g dosing. LEVEL OF EVIDENCE: I.
Authors: Manuel C Vallejo; Ahmed F Attaallah; Robert E Shapiro; Osama M Elzamzamy; Michael G Mueller; Warren S Eller Journal: J Anesth Date: 2016-10-12 Impact factor: 2.078
Authors: Kim A Boggess; Alan Tita; Victoria Jauk; George Saade; Sherri Longo; Erin A S Clark; Sean Esplin; Kristin Cleary; Ronald Wapner; Kelli Letson; Michelle Owens; Sean Blackwell; Carmen Beamon; Jeffrey M Szychowski; William Andrews Journal: Obstet Gynecol Date: 2017-03 Impact factor: 7.661
Authors: Hanadi H Alrammaal; Khaled Abduljalil; Victoria Hodgetts Morton; R Katie Morris; John F Marriott; Hsu P Chong; Hannah K Batchelor Journal: Pharmaceutics Date: 2022-05-30 Impact factor: 6.525
Authors: Amy M Valent; Chris DeArmond; Judy M Houston; Srinidhi Reddy; Heather R Masters; Alison Gold; Michael Boldt; Emily DeFranco; Arthur T Evans; Carri R Warshak Journal: JAMA Date: 2017-09-19 Impact factor: 56.272
Authors: Kevin R Theis; Roberto Romero; Andrew D Winters; Jonathan M Greenberg; Nardhy Gomez-Lopez; Ali Alhousseini; Janine Bieda; Eli Maymon; Percy Pacora; Jennifer M Fettweis; Gregory A Buck; Kimberly K Jefferson; Jerome F Strauss; Offer Erez; Sonia S Hassan Journal: Am J Obstet Gynecol Date: 2019-03 Impact factor: 10.693